Eli Lilly and Company | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2008 | $62,000,000 |
Endo Health Solution | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2014 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $173,000,000 |
Genentech Inc. | Roche | pharmaceuticals | off-label or unapproved promotion of medical products | 2000 | $19,000,000 |
GlaxoSmithKline | GlaxoSmithKline | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $477,792,391 |
Healthpoint Ltd. | | | off-label or unapproved promotion of medical products | 2013 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $28,000,000 |
Inspire Pharmaceuticals | Merck | pharmaceuticals | off-label or unapproved promotion of medical products | 2015 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $6,000,000 |
InterMune Inc. | Roche | pharmaceuticals | off-label or unapproved promotion of medical products | 2006 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $6,700,000 |
ISTA Pharmaceuticals, Inc. | Bausch Health | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $390,253 |
Janssen Pharmaceuticals, Inc. | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | $181,000,000 |
Johnson & Johnson | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $541,000,000 |
Medicis Pharmaceutical Corporation | Bausch Health | pharmaceuticals | off-label or unapproved promotion of medical products | 2007 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $4,000,000 |
Merck Sharp & Dohme Corp. | Merck | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $201,975,000 |
Novartis Pharmaceuticals Corporation | Novartis | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $88,258,694 |
Novartis Vaccines & Diagnostics Inc. and Novartis Pharmaceuticals Corporation | Novartis | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $29,000,000 |
Novo Nordisk Inc. | Novo Holdings A/S | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $3,574,209 |
Organon | Organon & Co. | pharmaceuticals | off-label or unapproved promotion of medical products | 2014 | $31,000,000 |
Ortho-McNeil Pharmaceutical LLC | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $24,681,516 |
Otsuka American Pharmaceutical Inc. | Otsuka Pharmaceutical | pharmaceuticals | off-label or unapproved promotion of medical products | 2008 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $1,700,000 |
Par Pharmaceutical Companies Inc. | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $22,500,000 |
Pfizer | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2014 | $35,000,000 |
Pfizer Inc. | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2008 | $60,000,000 |
Pfizer Inc. | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | $42,900,000 |
Purdue Pharma | Purdue Pharma | pharmaceuticals | off-label or unapproved promotion of medical products | 2007 | $19,500,000 |
Schering-Plough Corporation | Merck | pharmaceuticals | off-label or unapproved promotion of medical products | 2006 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $91,602,000 |
Serono Inc. | Merck KGaA (EMD) | pharmaceuticals | off-label or unapproved promotion of medical products | 2005 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $262,000,000 |
Shire Pharmaceuticals LLC | Takeda Pharmaceutical | pharmaceuticals | off-label or unapproved promotion of medical products | 2014 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $20,786,034 |
UCB Inc. | UCB | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $9,893,322 |
Warner-Lambert | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2004 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $190,000,000 |
Wyeth Pharmaceuticals, Inc. | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $257,400,000 |
McKinsey & Company | McKinsey | business services | off-label or unapproved promotion of medical products | 2021 | $573,000,000 |
Indivior plc | Indivior PLC | pharmaceuticals | off-label or unapproved promotion of medical products | 2021 | $300,000,000 |
Johnson & Johnson | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2021 | $5,000,000,000 |
Cardinal Health Inc. | Cardinal Health | wholesalers | off-label or unapproved promotion of medical products | 2021 | $6,489,000,000 |
AmerisourceBergen Corporation | AmerisourceBergen | wholesalers | off-label or unapproved promotion of medical products | 2021 | $6,510,000,000 |
McKesson Corporation | McKesson | wholesalers | off-label or unapproved promotion of medical products | 2021 | $8,001,000,000 |
Endo International plc | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | $450,000,000 |
Allergan | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | $2,370,000,000 |
Teva Pharmaceuticals | Teva Pharmaceutical Industries | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | $4,250,000,000 |
Walmart Stores | Walmart | retailing | off-label or unapproved promotion of medical products | 2022 | $3,100,000,000 |
Walgreens | Walgreens Boots Alliance | retailing | off-label or unapproved promotion of medical products | 2022 | $5,700,000,000 |
CVS | CVS Health | retailing | off-label or unapproved promotion of medical products | 2022 | $5,000,000,000 |
Walmart | Walmart | retailing | off-label or unapproved promotion of medical products | 2022 | $8,500,000 |
Teva Pharmaceutical Industries | Teva Pharmaceutical Industries | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | $8,200,000 |
Allergan | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | $4,800,000 |
Kroger | Kroger | retailing | off-label or unapproved promotion of medical products | 2023 | $1,370,000,000 |
Publicis Health | | | off-label or unapproved promotion of medical products | 2024 | $350,000,000 |
Hikma Pharmaceuticals | Hikma Pharmaceuticals | pharmaceuticals | off-label or unapproved promotion of medical products | 2024 | $150,000,000 |
BP | BP | oil and gas | oil spill | 2015 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $4,900,000,000 |
MOEX Offshore 2007 LLC | Mitsui | diversified | oil spill | 2012 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $25,000,000 |
Abbott Laboratories | AbbVie | pharmaceuticals | price-fixing or anti-competitive practices | 2005 | $15,350,000 |
Abbott Laboratories | AbbVie | pharmaceuticals | price-fixing or anti-competitive practices | 2010 | $22,500,000 |
ACE Group Holdings, Inc. | Chubb Limited | financial services | price-fixing or anti-competitive practices | 2007 | $4,500,000 |
ACE, Ltd | Chubb Limited | financial services | price-fixing or anti-competitive practices | 2006 | $80,000,000 |
Akzo Nobel Inc. | Carlyle Group | private equity (including portfolio companies) | price-fixing or anti-competitive practices | 2009 | $2,275,454 |
Alpharma, Inc. | Pfizer | pharmaceuticals | price-fixing or anti-competitive practices | 2004 | $750,000 |
American International Group, Inc. | American International Group | financial services | price-fixing or anti-competitive practices | 2008 | $12,500,000 |
Andrx Corporation | Teva Pharmaceutical Industries | pharmaceuticals | price-fixing or anti-competitive practices | 2003 | $40,000,000 |
Aon Corporation | Aon | financial services | price-fixing or anti-competitive practices | 2005 | $190,000,000 |
Apple Inc. | Apple Inc. | electrical and electronic equipment | price-fixing or anti-competitive practices | 2014 | $450,000,000 |
AU Optronics Corporation | AU Optronics | electrical and electronic equipment | price-fixing or anti-competitive practices | 2012 | $170,000,000 |
Aventis Animal Nutrition | | | price-fixing or anti-competitive practices | 2000 | $20,721,300 |
Aventis Pharmaceuticals Inc. | Sanofi | pharmaceuticals | price-fixing or anti-competitive practices | 2003 | $40,000,000 |
Aventis Pharmaceuticals, Inc. | Sanofi | pharmaceuticals | price-fixing or anti-competitive practices | 2012 | $1,650,000 |
Bank of America | Bank of America | financial services | price-fixing or anti-competitive practices | 2010 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $67,000,000 |
Barclays Bank PLC | Barclays | financial services | price-fixing or anti-competitive practices | 2016 | $100,000,000 |
Barr Pharmaceuticals | Teva Pharmaceutical Industries | pharmaceuticals | price-fixing or anti-competitive practices | 2008 | $5,900,000 |
BASF Corporation | BASF | chemicals | price-fixing or anti-competitive practices | 2000 | $62,258,250 |
Bausch & Lomb | Bausch Health | pharmaceuticals | price-fixing or anti-competitive practices | 2001 | $17,500,000 |
Bertelsmann Music Group Inc. | Sony | electrical and electronic equipment | price-fixing or anti-competitive practices | 2003 | $27,775,000 |
Bioproducts Incorporated | | | price-fixing or anti-competitive practices | 2009 | $2,275,454 |
Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | price-fixing or anti-competitive practices | 2003 | $55,000,000 |
Bristol-Myers Squibb Co. | Bristol-Myers Squibb | pharmaceuticals | price-fixing or anti-competitive practices | 2003 | $100,000,000 |
Bristol-Myers Squibb Company | Bristol-Myers Squibb | pharmaceuticals | price-fixing or anti-competitive practices | 2008 | $1,100,000 |
Chimei Innolux Corp. | Chi Mei Corporation | chemicals | price-fixing or anti-competitive practices | 2011 | $110,273,318 |
Chinook Global Limited | | | price-fixing or anti-competitive practices | 2009 | $2,275,454 |
Chubb | Chubb Limited | financial services | price-fixing or anti-competitive practices | 2006 | $17,000,000 |
Chunghwa Picture Tubes Ltd. | Tatung | electrical and electronic equipment | price-fixing or anti-competitive practices | 2011 | $5,305,105 |
CIBA Vision | Novartis | pharmaceuticals | price-fixing or anti-competitive practices | 2000 | $5,000,000 |
Citibank | Citigroup | financial services | price-fixing or anti-competitive practices | 2018 | $100,000,000 |
Daiichi Pharmaceutical | Daiichi Sankyo | pharmaceuticals | price-fixing or anti-competitive practices | 2000 | $4,340,100 |
Deutsche Bank | Deutsche Bank | financial services | price-fixing or anti-competitive practices | 2017 | $220,000,000 |
Duke Energy | Duke Energy | utilities and power generation | price-fixing or anti-competitive practices | 2004 | $207,500,000 |
E*Trade | Morgan Stanley | financial services | price-fixing or anti-competitive practices | 2012 | $100,000 |
Eisai | Eisai | pharmaceuticals | price-fixing or anti-competitive practices | 2000 | $7,634,700 |
El Paso Corporation | Kinder Morgan | pipelines | price-fixing or anti-competitive practices | 2003 | $1,450,000,000 |
Elpida Memory Inc. | Micron Technology | electrical and electronic equipment | price-fixing or anti-competitive practices | 2010 | $4,259,948 |
EMI Music Distribution | Sony | electrical and electronic equipment | price-fixing or anti-competitive practices | 2003 | $15,000,000 |
Encore Paper Co. | | | price-fixing or anti-competitive practices | 2000 | $300,000 |
Endo International plc | Endo International | pharmaceuticals | price-fixing or anti-competitive practices | 2019 | $2,300,000 |
Enron | | | price-fixing or anti-competitive practices | 2005 | $1,520,000,000 |
Epson | Seiko Group | electrical and electronic equipment | price-fixing or anti-competitive practices | 2011 | $2,850,000 |
Evonik Degussa GmbH | Evonik Industries | chemicals | price-fixing or anti-competitive practices | 2009 | $2,275,454 |
Ferring B.V. | | | price-fixing or anti-competitive practices | 2012 | $1,800,000 |
First Group, plc | FirstGroup | miscellaneous services | price-fixing or anti-competitive practices | 2007 | $1,100,000 |
Fort James Corp. | Koch Industries | diversified | price-fixing or anti-competitive practices | 2000 | $300,000 |
GE Funding Capital Market Services, Inc. | | | price-fixing or anti-competitive practices | 2011 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $34,250,000 |
Geneva Pharmaceuticals | Novartis | pharmaceuticals | price-fixing or anti-competitive practices | 2005 | $15,350,000 |
GlaxoSmithKline | GlaxoSmithKline | pharmaceuticals | price-fixing or anti-competitive practices | 2006 | $70,000,000 |
GlaxoSmithKline | GlaxoSmithKline | pharmaceuticals | price-fixing or anti-competitive practices | 2006 | $14,000,000 |
GlaxoSmithKline | GlaxoSmithKline | pharmaceuticals | price-fixing or anti-competitive practices | 2006 | $3,500,000 |
Hachette Book Group Inc. | | | price-fixing or anti-competitive practices | 2013 | $34,791,666 |